Table 2.
| A. Baseline and 48-week relevant clinical characteristics of 17 patients including hepatitis B virus (HBV) genotype and baseline mutations
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Age | Race | HIV | Baseline CD4, % |
HBV VL, copies/mL |
HIV VL, copies/ ml |
Liver fibrosis |
HBV genotype |
No. of mutations |
CODONS present and MT or WT |
| A1 | 40 | White | (+) | 163 (16) | 24,200,000 | <50 | 4 | A | 1 | 80 WT, 173 WT, 180/181 MT/WT, 236 WT |
| A3 | 47 | White | (+) | 309 (39) | 26,500,000,000 | 347 | 4 | A/G | 3 | 80 WT, 173 MT, 180/181 MT/WT, 204 MT, 236 WT |
| A4 | 65 | White | (+) | 238 (33) | 1,240,000,000 | 1556 | 4 | A/G | 3 | 80 WT+MT, 173 WT, 180/181 WT + MT/WT, 204 MT, 236 WT |
| N101 | 40 | White | (−) | 918(34) | 252,000,000 | <50 | 1 | A | 3 | 80 WT, 173 WT+MT, 180/181 MT/WT, 204 MT, 236 WT, 184 WT, 194 WT, 202 WT, 250 WT+MT |
| N102 | 30 | Black | (−) | 652 (36) | 82,000,000,000 | <50 | 3 | A | 3 | 80 WT, 173 MT, 180/181 MT/WT, 204 MT, 236 WT |
| N103 | 46 | Asian | (−) | 1169(37) | 19,000,000,000 | <50 | 3 | A | 3 | 80 WT+MT, 173 WT, 180/181 WT + MT/WT, 204 WT+MT, 236 WT |
| N104 | 17 | Asian | (−) | 816(40) | 33,700,000,000 | <50 | 3 | C | 2 | 80 WT+MT, 173 WT, 204 MT, 236 WT |
| N105 | 71 | White | (−) | 773 (38) | 2,160,000,000 | <50 | 3 | A | 2 | 80 WT, 173 WT, 180/181 MT/WT, 204 MT, 236 WT |
| P1 | 35 | White | (+) | 271 (20) | 7,700,000 | <50 | 1 | A/G | 3 | 80 WT, 173 MT, 180/181 MT/WT, 204 MT, 236 WT |
| P10 | 40 | Black | (+) | 396 (23) | 18,200,000,000 | <50 | 0 | A | 2 | 80 WT, 173 WT, 180/181 MT/WT, 204 MT, 236 WT |
| P2 | 37 | White | (+) | 558 (29) | 3,880,000,000 | <50 | 3 | A | 3 | 80 WT, 173 WT, 180/181 MT/WT, 204 MT, 236 WT |
| P3 | 37 | White | (+) | 979 (25) | 114,000,000,000 | <50 | 3 | A | 3 | 80 WT, 173 WT+MT, 180/181 MT/WT, 204 MT, 236 WT |
| P310 | 48 | White | (+) | 163 (16) | 1,260,000,000 | 739 | 4 | G | 3 | 80 WT, 173 WT+MT, 180/181 MT/WT, 204 MT, 236 WT |
| P4 | 37 | White | (+) | 87(5) | 55,300,000,000 | <50 | 1 | A | 3 | 80 WT, 173 WT+MT, 180/181 MT/WT, 204 MT, 236 WT |
| P5 | 32 | White | (+) | 576 (28) | 86,800,000,000 | 1907 | 3 | A | 3 | 80 WT, 173 WT+MT, 180/181 MT/WT, 204 MT, 236 WT |
| P8 | 57 | White | (+) | 775 (28) | 53,900,000 | 152 | 3 | A | 2 | 80 WT, 173 WT, 180/181 MT/WT, 204 MT, 236 WT |
| P9 | 36 | White | (+) | 852 (32) | 7,300,000,000 | <50 | 3 | A | 2 | 80 WT, 173 WT, 180/181 MT/WT, 204 MT, 236 WT |
| B. Hepatitis B virus serology status of all patients before and after treatment
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base line
|
48 Weeks
|
||||||||||||||
| Patient | HBsAg | HBeAg | antiHBe | antiHBs | antiHBc | ALT | AST | HBeAg seroconversion |
ALT | AST | HBsAg | HBeAg | anti HBe | antiHBs | antiHBc |
| N101 | (+) | (+) | (−) | (+) | (+) | 86 | 182 | No | 27 | 16 | (+) | (+) | (−) | (+) | (+) |
| N102 | (+) | (+) | (−) | (−) | (+) | 175 | 374 | Yes | 35 | 40 | (+) | (−) | (+) | QNS | (+) |
| N103 | (+) | (+) | (−) | (+) | (+) | 175 | 220 | No | 41 | 42 | (+) | (+) | (−) | Grayzone | (+) |
| N104 | (+) | (+) | (−) | (−) | (+) | 36 | 58 | No | 37 | 66 | (+) | (+) | (−) | (−) | (+) |
| N105 | (+) | (+) | (−) | (−) | (+) | 116 | 136 | No | 36 | 34 | (+) | (+) | (−) | (−) | (+) |
| P1 | (+) | (+) | (−) | (−) | (+) | 106 | 255 | No | 40 | 53 | (+) | (+) | (−) | (−) | (+) |
| P2 | (+) | (+) | (−) | (−) | (+) | 94 | 80 | No | 111 | 55 | (+) | (+) | (−) | (−) | (+) |
| P3 | (+) | (+) | (−) | (−) | (+) | 139 | 270 | No | 46 | 54 | (+) | (+) | (−) | (−) | (+) |
| P4 | (+) | (+) | (−) | (−) | (+) | 40 | 83 | No | 49 | 82 | (+) | (+) | (−) | (−) | (+) |
| P5 | (+) | (+) | (−) | (−) | (−) | 134 | 208 | No | 42 | 49 | (+) | (+) | (−) | (−) | (+) |
| P8 | (+) | (+) | (−) | (−) | (+) | 54 | 49 | No | 34 | 35 | (+) | (+) | (−) | (−) | (+) |
| P9 | (+) | (+) | (−) | (−) | (+) | 40 | 56 | No | 45 | 64 | (+) | (+) | (−) | (−) | (+) |
| P10 | (+) | (+) | (−) | (−) | (−) | 54 | 80 | No | 39 | 48 | (+) | (+) | (−) | (−) | (+) |
| P310 | (+) | (+) | (+) | (−) | (+) | 124 | 131 | No | 56 | 33 | (+) | (+) | (+/−) | (−) | (+) |
| A1 | (+) | (+) | (−) | (−) | (+) | 56 | 38 | No | 34 | 20 | (+) | (+) | (−) | (−) | (+) |
| A3 | (+) | (+) | (−) | (−) | (+) | 71 | 66 | No | 99 | 85 | (+) | (+) | (−) | (−) | (+) |
| A4 | (+) | (+) | (−) | (−) | (+) | 51 | 28 | Yes | 80 | 40 | (+) | (+) | (+) | (−) | (−) |
Note: Subject A2 (patient 18) died 24 weeks into the study. MT = mutations; VL = viral load; WT = wild type.
Note: Grayzone = equivocal results; QNS = quantity not sufficient.